Pasithea Therapeutics Corp. (KTTA) Institutional Ownership

Ownership Summary

The institutional landscape for Pasithea Therapeutics Corp. (NASDAQ:KTTA) includes 26 filers as of the latest reporting cycle ending December 2025.

• These investors collectively held 174.5% of the company's total shares outstanding in December 2025, up from 7.8% in September 2025.
• In percentage terms, this reflects as a holdings change of 2538.24% quarter on quarter, and an increase of 225.00% year over year.
• During the quarter, 20 institutions bought more Pasithea Therapeutics shares, 2 sold shares, and 4 of the 26 total investors held their position steady.
• The aggregate institutional position in Pasithea Therapeutics now stands at 12.93Mn shares as of December 2025, after investors increased their holdings (up by 12.44Mn shares quarter on quarter which is up 12.85Mn shares year over year).
• The top institutional stake in Pasithea Therapeutics as of December 31, 2025 belongs to JANUS HENDERSON GROUP PLC, which owns 2.10Mn shares, or 28.35% of the company.
• Among the most significant buyers of Pasithea Therapeutics during December 2025 were JANUS HENDERSON GROUP PLC (2.10Mn), Vivo Capital, LLC (2.10Mn), Squadron Capital Management LLC (2.10Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.10Mn), AMERIPRISE FINANCIAL INC (1.93Mn).
• Leading sellers of Pasithea Therapeutics stock in December 2025 included CITADEL ADVISORS LLC (11.16K), UBS Group AG (5.12K).
• The top 10 institutional holders of Pasithea Therapeutics for the quarter ending December 2025 included JANUS HENDERSON GROUP PLC (2.10Mn), Vivo Capital, LLC (2.10Mn), Squadron Capital Management LLC (2.10Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.10Mn), AMERIPRISE FINANCIAL INC (1.93Mn), Cable Car Capital, LP (500.00K), ACUTA CAPITAL PARTNERS, LLC (450.00K), STEMPOINT CAPITAL LP (355.08K), AdvisorShares Investments LLC (304.72K), Persistent Asset Partners Ltd (290.56K).